Amyotrophic lateral sclerosis with polyglucosan bodies

Summary

Amyotrophic lateral sclerosis with polyglucosan bodies (MONDO:0008782) is a disease. A subtype of amyotrophic lateral sclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	amyotrophic lateral sclerosis with polyglucosan bodies
Mondo ID	MONDO:0008782
MeSH	C565955
OMIM	205250
UMLS	C1859805
MedGen	347953
GARD	0015138
Is cancer (heuristic)	no

Also known as: amyotrophic lateral sclerosis with polyglucosan bodies

Disease family

This is a subtype of amyotrophic lateral sclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › spinal cord disorder › anterior horn disorder › amyotrophic lateral sclerosis › amyotrophic lateral sclerosis with polyglucosan bodies

Related subtypes (3): familial amyotrophic lateral sclerosis, sporadic amyotrophic lateral sclerosis, progressive muscular atrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.